Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Xenetic Biosciences Comprehensive Income 2013-2025 | XBIO

Xenetic Biosciences comprehensive income from 2013 to 2025. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
  
Xenetic Biosciences Annual Comprehensive Income
(Millions of US $)
2024 $0
2023 $0
2022 $0
2021 $0
2020 $0
2019 $0
2018 $0
2017 $0
2016 $0
2015 $0
2014 $1
2013 $1
2012 $1
2011 $0
Xenetic Biosciences Quarterly Comprehensive Income
(Millions of US $)
2025-03-31 $0
2024-12-31 $0
2024-09-30 $0
2024-06-30 $0
2024-03-31 $0
2023-12-31 $0
2023-09-30 $0
2023-06-30 $0
2023-03-31 $0
2022-12-31 $0
2022-09-30 $0
2022-06-30 $0
2022-03-31 $0
2021-12-31 $0
2021-09-30 $0
2021-06-30 $0
2021-03-31 $0
2020-12-31 $0
2020-09-30 $0
2020-06-30 $0
2020-03-31 $0
2019-12-31 $0
2019-09-30 $0
2019-06-30 $0
2019-03-31 $0
2018-12-31 $0
2018-09-30 $0
2018-06-30 $0
2018-03-31 $0
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $0
2015-09-30 $0
2015-06-30 $0
2015-03-31 $1
2014-12-31 $1
2014-09-30 $1
2014-06-30 $1
2014-03-31 $1
2013-12-31 $1
2013-09-30
2013-06-30
2013-03-31
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.005B $0.003B
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen(TM), its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen(TM) has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $86.587B 32.48
Zoetis (ZTS) United States $72.382B 27.01
Daiichi Sankyo, - (DSNKY) Japan $50.265B 25.57
Takeda Pharmaceutical (TAK) Japan $46.360B 9.22
Sandoz Group AG (SDZNY) Switzerland $21.683B 0.00
Summit Therapeutics (SMMT) United States $19.198B 0.00
Merck (MKKGY) Germany $16.795B 12.31
United Therapeutics (UTHR) United States $13.877B 12.28
Shionogi (SGIOY) Japan $13.799B 13.82
Neurocrine Biosciences (NBIX) United States $11.894B 40.74
IPSEN (IPSEY) France $9.790B 0.00
Orion OYJ (ORINY) Finland $9.323B 25.21
Corcept Therapeutics (CORT) United States $8.345B 67.84
Stevanato Group S.p.A (STVN) Italy $6.756B 41.31
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Madrigal Pharmaceuticals (MDGL) United States $5.941B 0.00
Grifols, S.A (GRFS) Spain $5.576B 0.00
Ionis Pharmaceuticals (IONS) United States $5.249B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.875B 14.83
Soleno Therapeutics (SLNO) United States $3.875B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.987B 10.47
Crinetics Pharmaceuticals (CRNX) United States $2.786B 0.00
Hypermarcas (HYPMY) Brazil $2.616B 17.21
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.244B 12.14
BioCryst Pharmaceuticals (BCRX) United States $2.216B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.934B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.719B 0.00
Evotec AG (EVO) Germany $1.680B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.659B 0.00
Indivior (INDV) United States $1.553B 6.58
ARS Pharmaceuticals (SPRY) United States $1.471B 0.00
Guardian Pharmacy Services (GRDN) United States $1.389B 0.00
Dyne Therapeutics (DYN) United States $1.329B 0.00
Ocular Therapeutix (OCUL) United States $1.163B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.092B 21.84
Harrow (HROW) United States $0.950B 0.00
Ardelyx (ARDX) United States $0.950B 0.00
Collegium Pharmaceutical (COLL) United States $0.927B 5.00
Avadel Pharmaceuticals (AVDL) Ireland $0.883B 0.00
Enliven Therapeutics (ELVN) United States $0.805B 0.00
Cronos Group (CRON) Canada $0.782B 0.00
Xeris Biopharma Holdings (XERS) United States $0.755B 0.00
Akebia Therapeutics (AKBA) United States $0.751B 0.00
AleAnna (ANNA) United States $0.675B 0.00
KalVista Pharmaceuticals (KALV) United States $0.570B 0.00
Elite Pharmaceuticals (ELTP) United States $0.566B 0.00
USANA Health Sciences (USNA) United States $0.548B 11.91
Regulus Therapeutics (RGLS) United States $0.546B 0.00
Xencor (XNCR) United States $0.539B 0.00
Bioventus (BVS) United States $0.536B 13.60
Relay Therapeutics (RLAY) United States $0.499B 0.00
Savara (SVRA) United States $0.491B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.473B 0.00
Zevra Therapeutics (ZVRA) United States $0.473B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.465B 0.00
Altimmune (ALT) United States $0.463B 0.00
CytoDyn (CYDY) United States $0.424B 0.00
Siga Technologies (SIGA) United States $0.422B 8.82
Oruka Therapeutics (ORKA) United States $0.410B 0.00
Tourmaline Bio (TRML) United States $0.393B 0.00
Verve Therapeutics (VERV) United States $0.389B 0.00
Organogenesis (ORGO) United States $0.368B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.339B 9.15
Heron Therapeutics (HRTX) United States $0.282B 0.00
Nature's Sunshine Products (NATR) United States $0.262B 24.19
Aquestive Therapeutics (AQST) United States $0.233B 0.00
MediWound (MDWD) Israel $0.220B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.212B 0.00
ProKidney (PROK) United States $0.208B 0.00
Nanobiotix S.A (NBTX) France $0.172B 0.00
Wellgistics Health (WGRX) United States $0.170B 0.00
OmniAb (OABI) United States $0.169B 0.00
Avita Medical (RCEL) United States $0.166B 0.00
Journey Medical (DERM) United States $0.163B 0.00
4D Molecular Therapeutics (FDMT) United States $0.162B 0.00
Esperion Therapeutics (ESPR) United States $0.157B 0.00
Profound Medical (PROF) Canada $0.154B 0.00
Liminatus Pharma (LIMN) $0.145B 0.00
Aclaris Therapeutics (ACRS) United States $0.136B 0.00
Aldeyra Therapeutics (ALDX) United States $0.133B 0.00
Inhibikase Therapeutics (IKT) United States $0.132B 0.00
Korro Bio (KRRO) United States $0.130B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.124B 0.00
Lyell Immunopharma (LYEL) United States $0.123B 0.00
Nektar Therapeutics (NKTR) United States $0.122B 0.00
Innate Pharma SA (IPHYF) France $0.122B 0.00
Protara Therapeutics (TARA) United States $0.121B 0.00
Larimar Therapeutics (LRMR) United States $0.120B 0.00
VAXART, INC (VXRT) United States $0.106B 0.00
Achieve Life Sciences (ACHV) Canada $0.105B 0.00
Cassava Sciences (SAVA) United States $0.102B 0.00
OptiNose (OPTN) United States $0.097B 0.00
Lexeo Therapeutics (LXEO) United States $0.094B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.092B 0.00
Cardiol Therapeutics (CRDL) Canada $0.091B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.091B 0.00
Fractyl Health (GUTS) United States $0.088B 0.00
Arch Biopartners (ACHFF) Canada $0.084B 0.00
Galectin Therapeutics (GALT) United States $0.081B 0.00
Champions Oncology (CSBR) United States $0.080B 13.18
Pyxis Oncology (PYXS) United States $0.076B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.076B 56.44
ESSA Pharma (EPIX) Canada $0.075B 0.00
Inotiv (NOTV) United States $0.073B 0.00
Surrozen (SRZN) United States $0.068B 0.00
Dominari Holdings (DOMH) United States $0.067B 0.00
Assertio Holdings (ASRT) United States $0.067B 0.00
Vivani Medical (VANI) United States $0.067B 0.00
Unicycive Therapeutics (UNCY) United States $0.067B 0.00
Telomir Pharmaceuticals (TELO) United States $0.063B 0.00
Context Therapeutics (CNTX) United States $0.062B 0.00
Nutriband (NTRB) United States $0.061B 0.00
Metagenomi (MGX) United States $0.061B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.057B 0.00
Gain Therapeutics (GANX) United States $0.053B 0.00
Prelude Therapeutics (PRLD) United States $0.050B 0.00
Century Therapeutics (IPSC) United States $0.048B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.048B 0.00
Mural Oncology (MURA) Ireland $0.047B 0.00
PMV Pharmaceuticals (PMVP) United States $0.047B 0.00
NRx Pharmaceuticals (NRXP) United States $0.045B 0.00
Avalo Therapeutics (AVTX) United States $0.041B 0.00
Karyopharm Therapeutics (KPTI) United States $0.040B 0.00
Iterum Therapeutics (ITRM) Ireland $0.037B 0.00
ElectroCore (ECOR) United States $0.037B 0.00
Acrivon Therapeutics (ACRV) United States $0.037B 0.00
Rafael Holdings (RFL) United States $0.035B 0.00
FibroGen (FGEN) United States $0.033B 0.00
SCYNEXIS (SCYX) United States $0.030B 0.00
PolyPid (PYPD) Israel $0.028B 0.00
China SXT Pharmaceuticals (SXTC) China $0.025B 0.00
Enlivex Therapeutics (ENLV) Israel $0.023B 0.00
CASI Pharmaceuticals (CASI) China $0.023B 0.00
Tempest Therapeutics (TPST) United States $0.023B 0.00
Relmada Therapeutics (RLMD) United States $0.021B 0.00
Natural Alternatives (NAII) United States $0.021B 0.00
Jupiter Neurosciences (JUNS) United States $0.021B 0.00
Lipocine (LPCN) United States $0.019B 0.00
BioVie (BIVI) United States $0.019B 0.00
Mannatech (MTEX) United States $0.018B 0.00
DURECT (DRRX) United States $0.017B 0.00
TherapeuticsMD (TXMD) United States $0.017B 0.00
VYNE Therapeutics (VYNE) United States $0.016B 0.00
GlycoMimetics (GLYC) United States $0.016B 0.00
SHINECO (SISI) China $0.015B 0.00
Ernexa Therapeutics (ERNA) United States $0.014B 0.00
Vivos Therapeutics (VVOS) United States $0.013B 0.00
ProPhase Labs (PRPH) United States $0.013B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.013B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.012B 0.00
Scienture Holdings (SCNX) United States $0.011B 0.00
Talphera (TLPH) United States $0.010B 0.00
Minerva Neurosciences (NERV) United States $0.010B 1.78
Ainos (AIMD) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Mangoceuticals (MGRX) United States $0.009B 0.00
Phio Pharmaceuticals (PHIO) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Carisma Therapeutics (CARM) United States $0.008B 0.00
Traws Pharma (TRAW) United States $0.007B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Citius Pharmaceuticals (CTXR) United States $0.007B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.007B 0.00
Incannex Healthcare (IXHL) Australia $0.006B 0.00
Klotho Neurosciences (KLTO) United States $0.006B 0.00
Lyra Therapeutics (LYRA) United States $0.006B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Plus Therapeutics (PSTV) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
CERo Therapeutics Holdings (CERO) United States $0.004B 0.00
PainReform (PRFX) Israel $0.004B 0.00
Aditxt (ADTX) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Redhill Biopharma (RDHL) Israel $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Conduit Pharmaceuticals (CDT) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
MEI Pharma (MEIP) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00